-
Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab Liver Int. (IF 6.7) Pub Date : 2024-03-16 Tatsuya Kikuchi, Yasuto Takeuchi, Kazuhiro Nouso, Kazuya Kariyama, Kenji Kuwaki, Junichi Toshimori, Shota Iwado, Akio Moriya, Hiroaki Hagihara, Hiroyuki Takabatake, Toshifumi Tada, Tetsuya Yasunaka, Masahiro Sakata, Masahiko Sue, Nozomi Miyake, Takuya Adachi, Nozomu Wada, Hideki Onishi, Hidenori Shiraha, Akinobu Takaki, Motoyuki Otsuka
BackgroundTo identify predictive factors associated with successful transition to conversion therapy following combination therapy with atezolizumab and bevacizumab in the treatment of unresectable hepatocellular carcinoma (HCC).MethodsIn total, 188 patients with HCC, who received atezolizumab plus bevacizumab combination therapy as the first‐line chemotherapy, were studied. Patients who achieved complete
-
The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease Liver Int. (IF 6.7) Pub Date : 2024-03-16 Hye Won Lee, Kun Hee Kim, Sang Hoon Ahn, Han Chu Lee, Jonggi Choi
BackgroundThe prognosis of metabolic dysfunction‐associated steatotic liver disease (MASLD) is associated with liver fibrosis. We investigated the associations between changes in liver stiffness measurement (LSM) over 3‐year period and the development of cirrhosis or hepatocellular carcinoma (HCC) in patients with MASLD.MethodsThis study involved patients with MASLD who underwent transient elastography
-
An optimized short‐term steroid therapy for chronic drug‐induced liver injury: A prospective randomized clinical trial Liver Int. (IF 6.7) Pub Date : 2024-03-14 Ang Huang, Yun Zhu, Shuhong Liu, Ying Sun, Zherui Liu, Qing‐sheng Liang, Jun Zhao, Bin‐xia Chang, Jing‐feng Bi, Jiang‐tao Liu, Xing‐ran Zhai, Huan Xie, Ning Li, Hui Tian, Lin Han, Yingjie Zhuang, Hongbin Ma, Guang‐ju Teng, Wei Zhang, Guruprasad P. Aithal, Dong Ji, Jingmin Zhao, Zhengsheng Zou
Background and AimsThe use of corticosteroids in chronic drug‐induced liver injury (DILI) is an important issue. Our previous randomized controlled trial showed that patients with chronic DILI benefited from a 48‐week steroid stepwise reduction (SSR) regimen. However, it remains unclear whether a shorter course of therapy can achieve similar efficacy. In this study, we aimed to assess whether a 36‐week
-
Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes Liver Int. (IF 6.7) Pub Date : 2024-03-08 Huey‐Ling Chen, Chien‐Nan Lee, Chin‐Hao Chang, Ming‐Wei Lai, Ming‐Chieh Tsai, Shu‐Chi Mu, Chun‐Jen Liu, Jin‐Chung Shih, Wan‐Hsin Wen, Rui‐Ting Hu, Chun‐Pin Huang, Kuang‐Chun Hu, Chie‐Pein Chen, Chyi‐Long Lee, Rong‐Nan Chien, Kai‐Chi Chang, Hong‐Yuan Hsu, Chien‐Chang Lee, Yen‐Hsuan Ni, Mei‐Hwei Chang
BackgroundThe use of antiviral agents, specifically tenofovir disoproxil fumarate (TDF), in pregnant women to prevent mother‐to‐child HBV transmission is a key step towards hepatitis elimination. However, data on using tenofovir alafenamide (TAF) is insufficient. The frequent occurrence of postpartum ALT flares may impact the clinical implementation.MethodsThe maternal and infant outcomes were compared
-
Proactive case finding of alcohol‐related liver disease in high‐risk populations: A systematic review Liver Int. (IF 6.7) Pub Date : 2024-03-08 Ann J. Archer, Jennifer Phillips, Mohsan Subhani, Zoe Ward, Fiona H. Gordon, Matthew Hickman, Ashwin D. Dhanda, Kushala W. M. Abeysekera
BackgroundAlcohol‐related liver disease (ARLD) is often diagnosed at a late stage when mortality is unacceptably high. Earlier identification of ARLD may lead to reduced alcohol intake, participation in hepatocellular carcinoma surveillance and reduction in liver‐related morbidity and mortality. People with alcohol use disorder (AUD) are at highest risk of ARLD. The aim of this systematic review was
-
Liver transplantation and primary liver cancer in porphyria Liver Int. (IF 6.7) Pub Date : 2024-03-08 Mattias Lissing, Bruce Wang, Staffan Wahlin
The porphyrias are a heterogeneous group of metabolic disorders that result from defects in heme synthesis. The metabolic defects are present in all cells, but symptoms are mainly cutaneous or related to neuropathy. The porphyrias are highly relevant to hepatologists since patients can present with symptoms and complications that require liver transplantation (LT), and some porphyrias are associated
-
Drug-induced liver injury (DILI) ascribed to non-steroidal anti-inflammatory drugs (NSAIDs) in the USA—Update with genetic correlations Liver Int. (IF 6.7) Pub Date : 2024-03-07 Herbert L. Bonkovsky, Marwan Ghabril, Paola Nicoletti, Andrew Dellinger, Robert J. Fontana, Huiman Barnhart, Jiezhun Gu, Ann K. Daly, Guruprasad P. Aithal, Elizabeth J. Phillips, David E. Kleiner
To describe patients with NSAID-DILI, including genetic factors associated with idiosyncratic DILI.
-
Hepatic organoids move from adolescence to maturity Liver Int. (IF 6.7) Pub Date : 2024-03-07 Yuan Guan, Gary Peltz
Since organoids were developed 15 years ago, they are now in their adolescence as a research tool. The ability to generate ‘tissue in a dish’ has created enormous opportunities for biomedical research. We examine the contributions that hepatic organoids have made to three areas of liver research: as a source of cells and tissue for basic research, for drug discovery and drug safety testing, and for
-
Recipient age influences survival after liver transplant: Results of the French national cohort 2007–2017 Liver Int. (IF 6.7) Pub Date : 2024-03-07 Lea Lerosey, Elea Ksiasek, Michal Abrahamowicz, Corinne Antoine, Sébastien Dharancy, Jérôme Dumortier, Alexandre Doussot, Vincent Di Martino, Pauline Houssel‐Debry, Filomena Conti, Claire Francoz, Georges‐Philippe Pageaux, Ephrem Salame, François Faitot, Audrey Coilly, Jean Hardwigsen, Thomas Decaens, Faiza Chermak, Fabrice Muscari, Rodolphe Anty, Christophe Duvoux, Armand Abergel, Anne Minello, Thomas
BackgroundIn recent years, age at liver transplantation (LT) has markedly increased. In the context of organ shortage, we investigated the impact of recipient age on post‐transplantation mortality.MethodsAll adult patients who received a first LT between 2007 and 2017 were included in this cross‐sectional study. Recipients' characteristics at the time of listing, donor and surgery data, post‐operative
-
Impact of new direct‐acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection Liver Int. (IF 6.7) Pub Date : 2024-03-06 Farinaz Forouzannia, Abdullah Hamadeh, Ana Maria Passos‐Castilho, Aysegul Erman, Amanda Yu, Zeny Feng, Naveed Z. Janjua, Beate Sander, Christina Greenaway, William W. L. Wong
BackgroundPatients with chronic hepatitis C (CHC) can be cured with the new highly effective interferon‐free combination treatments (DAA) that were approved in 2014. However, CHC is a largely silent disease, and many individuals are unaware of their infections until the late stages of the disease. The impact of wider access to effective treatments and improved awareness of the disease on the number
-
Health information in short videos about metabolic dysfunction‐associated steatotic liver disease: Analysing quality and reliability Liver Int. (IF 6.7) Pub Date : 2024-03-05 Ruihao Ding, Qingzhou Kong, Longfei Sun, Xuyan Liu, Leiqi Xu, Yueyue Li, Xiuli Zuo, Yanqing Li
Background & AimsShort videos, crucial for disseminating health information on metabolic dysfunction‐associated steatotic liver disease (MASLD), lack a clear evaluation of quality and reliability. This study aimed to assess the quality and reliability of MASLD‐related videos on Chinese platforms.MethodsVideo samples were collected from three platforms (TikTok, Kwai and Bilibili) during the period from
-
Multitask deep learning for prediction of microvascular invasion and recurrence‐free survival in hepatocellular carcinoma based on MRI images Liver Int. (IF 6.7) Pub Date : 2024-03-04 Fang Wang, Gan Zhan, Qing‐qing Chen, Hou‐yun Xu, Dan Cao, Yuan‐yuan Zhang, Yin‐hao Li, Chu‐jie Zhang, Yao Jin, Wen‐bin Ji, Jian‐bing Ma, Yun‐jun Yang, Wei Zhou, Zhi‐yi Peng, Xiao Liang, Li‐ping Deng, Lan‐fen Lin, Yen‐wei Chen, Hong‐jie Hu
Background and AimsAccurate preoperative prediction of microvascular invasion (MVI) and recurrence‐free survival (RFS) is vital for personalised hepatocellular carcinoma (HCC) management. We developed a multitask deep learning model to predict MVI and RFS using preoperative MRI scans.MethodsUtilising a retrospective dataset of 725 HCC patients from seven institutions, we developed and validated a multitask
-
Long‐term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma Liver Int. (IF 6.7) Pub Date : 2024-03-04 Clémentine Alitti, Agnès Rode, Hervé Trillaud, Philippe Merle, Jean‐Frédéric Blanc, Lorraine Blaise, Alix Demory, Gisele Nkontchou, Véronique Grando, Marianne Ziol, Pierre Nahon, Nathalie Ganne‐Carrié, Arthur Petit, Olivier Seror, Olivier Sutter, Jean‐Charles Nault
IntroductionThe effectiveness of percutaneous radiofrequency ablation (RFA) in intrahepatic cholangiocarcinomas (iCCA) remains insufficiently studied.MethodsWe conducted a retrospective study including patients with histologically proven iCCA within Milan criteria treated by percutaneous RFA from 2000 to 2022. The primary outcome was overall survival in treatment‐naive patients and secondary outcomes
-
Progression pattern and post‐progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma Liver Int. (IF 6.7) Pub Date : 2024-03-04 Satoshi Kobayashi, Taito Fukushima, Makoto Ueno, Makoto Chuma, Kazushi Numata, Kota Tsuruya, Yoshitaka Arase, Shunji Hirose, Tatehiro Kagawa, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Haruki Uojima, Hisashi Hidaka, Chika Kusano, Manabu Morimoto, Shin Maeda
BackgroundAlthough the combination of atezolizumab and bevacizumab (ATZ + BEV) is a standard treatment for advanced hepatocellular carcinoma (HCC), strategies for addressing treatment failure and prognostic factors of post‐progression survival (PPS) remain unestablished.MethodsWe conducted a multicentre retrospective study to evaluate PPS following ATZ + BEV treatment in patients with advanced HCC
-
Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma Liver Int. (IF 6.7) Pub Date : 2024-03-01 Edoardo G. Giannini, Andrea Pasta, Giulia Pieri, Maria Corina Plaz Torres, Mariarosaria Marseglia, Filippo Pelizzaro, Angelo Sangiovanni, Giuseppe Cabibbo, Giorgia Ghittoni, Mariella Di Marco, Francesco Giuseppe Foschi, Maria Guarino, Elisabetta Biasini, Carlo Saitta, Claudia Campani, Gianluca Svegliati-Baroni, Antonio Gasbarrini, Maurizia Rossana Brunetto, Donatella Magalotti, Francesco Azzaroli,
Chronic hepatitis D virus (HDV) often leads to end-stage liver disease and hepatocellular carcinoma (HCC). Comprehensive data pertaining to large populations with HDV and HCC are missing, therefore we sought to assess the characteristics, management, and outcome of these patients, comparing them to patients with hepatitis B virus (HBV) infection.
-
Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort Liver Int. (IF 6.7) Pub Date : 2024-03-01 Liang‐Jie Tang, Dan‐Qin Sun, Sherlot Juan Song, Terry Cheuk‐Fung Yip, Grace Lai‐Hung Wong, Pei‐Wu Zhu, Sui‐Dan Chen, Morten Karsdal, Diana Julie Leeming, Pei Jiang, Cong Wang, Qiang Chen, Christopher D. Byrne, Giovanni Targher, Mohammed Eslam, Jacob George, Vincent Wai‐Sun Wong, Ming‐Hua Zheng
BackgroundMetabolic dysfunction‐associated fatty liver disease (MAFLD) is an emerging risk factor for chronic kidney disease (CKD). N‐terminal propeptide of collagen type 3 (PRO‐C3) is a biomarker of advanced fibrosis in MAFLD and PRO‐C3 may be involved in renal fibrosis. We aimed to use PRO‐C3 measurements to generate a new algorithmic score to test the prediction of MAFLD with chronic kidney disease
-
Artificial replication cohort: Leveraging AI‐fabricated data for genetic studies Liver Int. (IF 6.7) Pub Date : 2024-03-01 Wiktor Smyk, Krystian Adrych, Marcin Krawczyk
Recent advancements in artificial intelligence (AI) present both opportunities and challenges within the scientific community. This study explores the capability of AI to replicate findings from genetic research, focusing on findings from prior work. Using an AI model without exposing any raw data, we created a dataset that closely mirrors the results of our original study, illustrating the ease of
-
Global burden of acute hepatitis E between 1990 and 2019 and projections until 2030 Liver Int. (IF 6.7) Pub Date : 2024-03-01 Guoqing Ouyang, Guangdong Pan, Qiuyun Li, Shuang Li, Tao Liu, Xiaolei Yi, Zhipeng Liu
Background and AimsAcute hepatitis E (AHE) is still a public health issue worldwide. Here, we report the global burden of AHE in 204 countries and territories from 1990 to 2019 by age, sex and socio‐demographic index (SDI), and predict the future trends to 2030.MethodsData on AHE were collected from the Global Burden of Diseases, Injuries and Risk Factors Study 2019. The average annual percentage change
-
Acute and non‐acute decompensation of liver cirrhosis (47/130) Liver Int. (IF 6.7) Pub Date : 2024-03-01 Martin S. Schulz, Paolo Angeli, Jonel Trebicka
In the traditional view, the occurrence of cirrhosis‐related complications, such as hepatic encephalopathy, formation of ascites or variceal haemorrhage, marks the transition to the decompensated stage of cirrhosis. Although the dichotomous stratification into a compensated and decompensated state reflects a prognostic water‐shed moment and remains to hold its prognostic validity, it represents an
-
Combination of heterozygous APOB gene mutation with PNPLA3 and TM6SF2 variants promotes steatotic liver disease, cirrhosis and HCC development Liver Int. (IF 6.7) Pub Date : 2024-02-29 Yasmina Chouik, Mathilde Di Filippo, Sylvie Radenne, Jérôme Dumortier, Philippe Moulin, Massimo Levrero
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease worldwide. In recent years, several single nucleotide polymorphisms (SNPs) in genes involved in hepatic lipid metabolism (PNPLA3, TM6SF2, GCKR, MBOAT7 and HSD17B13) have been shown to significantly contribute to the emergence of the disease in association with environmental factors.1-3 Monogenic disorders
-
-
Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study Liver Int. (IF 6.7) Pub Date : 2024-02-26 Majd B. Aboona, Claire Faulkner, Pooja Rangan, Cheng Han Ng, Daniel Q. Huang, Mark Muthiah, Moises I. Nevah Rubin, Ma Ai Thanda Han, Michael B. Fallon, Donghee Kim, Vincent L. Chen, Karn Wijarnpreecha
BackgroundMetabolic dysfunction‐associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease and 10%–20% occurs in lean individuals. There is little data in the literature regarding outcomes in an ethnically‐diverse patient populations with MASLD. Thus, we aim to investigate the natural history and ethnic disparities of MASLD patients in a diverse population, and stratified
-
Plastic compounds and liver diseases: Whether bisphenol A is the only culprit Liver Int. (IF 6.7) Pub Date : 2024-02-26 Sonal Sangwan, Rajasri Bhattacharyya, Dibyajyoti Banerjee
Plastics, while providing modern conveniences, have become an inescapable source of global concern due to their role in environmental pollution. Particularly, the focus on bisphenol A (BPA) reveals its biohazardous nature and association with liver issues, specifically steatosis. However, research indicates that BPA is just one facet of the problem, as other bisphenol analogues, microplastics, nanoplastics
-
Inflammatory myofibroblastoma mimicking cavernous hemangioma in the liver Liver Int. (IF 6.7) Pub Date : 2024-02-26 Hong Yang, Binglin Lai
A 37‐year‐old female patient was admitted to the hospital with a large liver mass, diagnosed as hepatic inflammatory myofibroblastic tumour (HIMT), characterized by unique radiographic features and predominantly occurring in adults. HIMT consists of myofibroblast spindle cells infiltrated by plasma cells and/or lymphocytes, with an unclear aetiology linked to factors like infection and immune response
-
Prevalence of hepatic steatosis and fibrosis in Turner syndrome: A prospective case–control study Liver Int. (IF 6.7) Pub Date : 2024-02-23 Patrick Twohig, Ling Li, David Danford, Mary Craft, Anji T. Yetman
Background and AimsAbnormal liver chemistries are common in Turner syndrome (TS). Guidelines suggest that TS patients undergo annual screening of liver enzymes, but the role of non‐invasive screening for steatosis and fibrosis is not clearly defined. We compared the prevalence of hepatic steatosis and fibrosis among TS patients to healthy controls using ultrasound with shear‐wave elastography (SWE)
-
Risk of major adverse liver outcomes among first‐degree relatives of individuals with MASLD Liver Int. (IF 6.7) Pub Date : 2024-02-22 Wen Yang, Fahim Ebrahimi, Stefano Romeo, Magnus Holmer, Johan Vessby, Mattias Ekstedt, Jonas F. Ludvigsson, Ying Shang, Hannes Hagström
Background & AimsPrevious studies have suggested an increased risk of major adverse liver outcomes (MALO) in relatives of patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). However, granular and longitudinal evidence is lacking on the future risk of MALO among family members of individuals with MASLD.MethodsWe identified 3526 first‐degree relatives (FDRs) and 11 079 general
-
Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: A systematic review Liver Int. (IF 6.7) Pub Date : 2024-02-22 Annalisa Cespiati, Inês Coelho Rodrigues, Inês Santos, Sara Policarpo, Sofia Carvalhana, Anna Ludovica Fracanzani, Helena Cortez‐Pinto
Background and AimsThe beneficial effect of Hepatitis C virus (HCV) eradication by direct antiviral agents (DAAs) on liver fibrosis is well defined. Despite this, the impact of viral eradication in both hepatic and extra‐hepatic metabolic features is underreached. This systematic review aimed to synthesize the evidence on the impact of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis
-
Improving the hepatitis C virus care cascade with the in‐hospital Reflex tEsting ALarm‐C (REAL‐C) model Liver Int. (IF 6.7) Pub Date : 2024-02-20 Jonggi Choi, Jina Park, Won‐Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Sujin Kwon, Sang‐Hyun Hwang
BackgroundThe World Health Organization (WHO) has set targets to eliminate viral hepatitis, including hepatitis C virus (HCV) infection, by 2030. We present the results of the in‐hospital Reflex tEsting ALarm‐C (REAL‐C) model, which incorporates reflex HCV RNA testing and sending alerts to physicians.MethodsWe conducted a retrospective study analysing the data of 1730 patients who newly tested positive
-
Mitochondrial amidoxime‐reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome Liver Int. (IF 6.7) Pub Date : 2024-02-20 Tanmoy Dutta, Kavitha Sasidharan, Ester Ciociola, Grazia Pennisi, Francesca R. Noto, Lohitesh Kovooru, Tobias Kroon, Anna Lindblom, Yue Du, Mohammad Pirmoradian, Simonetta Wallin, Rosellina M. Mancina, Daniel Lindén, Stefano Romeo
ObjectiveMetabolic dysfunction‐associated steatotic liver disease (MASLD) is a global health concern with no effective and specific drug treatment available. The rs2642438 minor allele in mitochondrial amidoxime‐reducing component 1 (MARC1) results in an aminoacidic substitution (p.Ala165Thr) and associates with protection against MASLD. However, the mechanisms behind this protective effect are unknown
-
Real‐world economic burden of hepatitis C and impact of direct‐acting antivirals in France: A nationwide claims data analysis Liver Int. (IF 6.7) Pub Date : 2024-02-20 Laurent Lam, Patrizia Carrieri, Gilles Hejblum, Jonathan Bellet, Marc Bourlière, Fabrice Carrat
Background and AimsThe economic impact of managing patients with hepatitis C virus (HCV) infection remains unknown. This study aimed to assess the economic burden of chronic HCV infection from a national health insurance perspective and the impact of direct‐acting antivirals (DAAs) using nationwide real‐world data.MethodsPatients with chronic HCV infection were identified from the French Health Insurance
-
Characterization of lymphocyte-rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures Liver Int. (IF 6.7) Pub Date : 2024-02-16 Bokyung Ahn, Hee-Sung Ahn, Jinho Shin, Eunsung Jun, Eun-Young Koh, Yeon-Mi Ryu, Sang-Yeob Kim, Chang Ohk Sung, Ju Hyun Shim, JeongYeon Hong, Kyunggon Kim, Hyo Jeong Kang
Lymphocyte-rich hepatocellular carcinoma (LR-HCC) is largely unknown and a rare subtype of HCC with immune-rich stroma. Tertiary lymphoid structures (TLS), frequently observed in LR-HCC, are known to be prognostically significant in various malignancies; however, their significance in HCC remains unevaluated.
-
Comparative metabolome analysis reveals higher potential of haemoperfusion adsorption in providing favourable outcome in ACLF patients Liver Int. (IF 6.7) Pub Date : 2024-02-15 Manisha Yadav, Rakhi Maiwal, Vinay Kumar BR, Gaurav Tripathi, Neha Sharma, Nupur Sharma, Vasundhra Bindal, Babu Mathew, Sushmita Pandey, Satender Pal Singh, Harsh Vardhan Tevathia, Jaswinder Singh Maras, Shiv Kumar Sarin
Acute-on-chronic liver failure (ACLF) is a serious illness associated with altered metabolome, organ failure and high mortality. Need for therapies to improve the metabolic milieu and support liver regeneration are urgently needed.
-
Performance of continuous controlled attenuation parameter and liver stiffness measurement by the novel SmartExam in metabolic dysfunction-associated steatotic liver disease Liver Int. (IF 6.7) Pub Date : 2024-02-14 Sherlot J. Song, Asako Nogami, Lilian Y. Liang, Masato Yoneda, Howard H.W. Leung, Atsushi Nakajima, Jimmy C.T. Lai, Grace L.H. Wong, Sally S.T. Shu, Vincent W.S. Wong, Terry C.F. Yip
FibroScan® Expert 630 and FibroScan® Mini+430 are novel vibration-controlled transient elastography devices equipped with the same SmartExam software, which allows continuous measurement of controlled attenuation parameter (CAP) during the entire examination. This study aims to compare the CAP variabilities and the quantification for liver fibrosis and steatosis between the conventional FibroScan and
-
Association of sex hormones with non-alcoholic fatty liver disease: An observational and Mendelian randomization study Liver Int. (IF 6.7) Pub Date : 2024-02-12 Chenghao Weng, Zilun Shao, Meng Xiao, Mingyu Song, Yuxuan Zhao, Aolin Li, Yuanjie Pang, Tao Huang, Canqing Yu, Jun Lv, Liming Li, Dianjianyi Sun
Sex-specific associations of sex hormone-binding globulin (SHBG) and bioavailable testosterone (BAT) with NAFLD remain indeterminate. We aimed to explore observational and genetically determined relationships between each hormone and NAFLD.
-
Red meat intake, faecal microbiome, serum trimethylamine N-oxide and hepatic steatosis among Chinese adults Liver Int. (IF 6.7) Pub Date : 2024-02-05 Yong Huang, Jiawei Zhang, Yaozong Zhang, Wuqi Wang, Meiling Li, Bo Chen, Xiaoyu Zhang, Zhuang Zhang, Jiaqi Huang, Yong Jin, Hua Wang, Xuehong Zhang, Shi Yin, Wanshui Yang
Emerging evidence suggests a detrimental impact of high red meat intake on hepatic steatosis. We investigated the potential interplay between red meat intake and gut microbiome on circulating levels of trimethylamine N-oxide (TMAO) and hepatic steatosis risk.
-
Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa Liver Int. (IF 6.7) Pub Date : 2024-02-02 Zobair M. Younossi, Pegah Golabi, James Paik, Soroor Owrangi, Yusuf Yilmaz, Mohamed El-Kassas, Khalid Alswat, Saleh A. Alqahtani
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is common and closely associated with type 2 diabetes (T2D). We assessed the prevalence of NAFLD/MASLD in the general population and among patients with T2D in the Middle East and North Africa (MENA) region.
-
Cardiac remodelling in non-alcoholic fatty liver disease in the general population Liver Int. (IF 6.7) Pub Date : 2024-01-31 Frederik Kostka, Till Ittermann, Stefan Groß, Fabian Christopher Laqua, Robin Bülow, Henry Völzke, Marcus Dörr, Jens Peter Kühn, Marcello Ricardo Paulista Markus, Marie-Luise Kromrey
Non-alcoholic fatty liver disease (NAFLD) is associated with increased risk for cardiovascular disease. Our study investigates the contribution of NAFLD to changes in cardiac structure and function in a general population.
-
Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020 Liver Int. (IF 6.7) Pub Date : 2024-01-31 Brendan L. Harney, Rachel Sacks-Davis, Daniela K. van Santen, Michael W. Traeger, Anna L. Wilkinson, Jason Asselin, Christopher K. Fairley, Norman Roth, Mark Bloch, Gail V. Matthews, Basil Donovan, Rebecca Guy, Mark Stoové, Margaret E. Hellard, Joseph S. Doyle
There is some concern that hepatitis C virus (HCV) reinfection might impact HCV micro-elimination efforts among gay and bisexual men (GBM) with HIV. However, there is a limited understanding of reinfection incidence in the context of unrestricted government-funded HCV treatment. We aimed to estimate HCV reinfection incidence among GBM with HIV in Australia from 2016 to 2020.
-
Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus Liver Int. (IF 6.7) Pub Date : 2024-01-31 Natália Coelho Lavrado, Gil Fernando Salles, Claudia Regina Lopes Cardoso, Paulo Henrique Condeixa de França, Maria Fernanda Di Guimarães Gonçalves Melo, Nathalie Carvalho Leite, Cristiane Alves Villela-Nogueira
Longitudinal studies assessing the impact of genetic polymorphisms on outcomes in patients with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) are scarce. This study aimed to evaluate the effect of PNPLA3 and TM6SF2 risk alleles on hepatic and extrahepatic outcomes in T2DM-MASLD individuals.
-
Cirrhosis-downregulated LSECtin can be retrieved by cytokines, shifts the TLR-induced LSECs secretome and correlates with the hepatic Th response Liver Int. (IF 6.7) Pub Date : 2024-01-31 Sebastián Martínez-López, Enrique Ángel-Gomis, Isabel Gómez-Hurtado, Anabel Fernández-Iglesias, Javier Morante, Jordi Gracia-Sancho, Paula Boix, Francisco J. Cubero, Pedro Zapater, Esther Caparrós, Rubén Francés
We evaluated tolerogenic C-type lectin LSECtin loss in cirrhosis and its potential regulation by cytokines.
-
Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults Liver Int. (IF 6.7) Pub Date : 2024-01-31 Rui Song, Zhao Li, Yingzhi Zhang, Jiahe Tan, Zhiwei Chen
Following the classification of metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic fatty liver disease (NAFLD) has recently been redefined again as metabolic dysfunction-associated steatotic liver disease (MASLD). However, the distinctions in characteristics and mortality outcomes between NAFLD, MAFLD and MASLD remain unclear.
-
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH Liver Int. (IF 6.7) Pub Date : 2024-01-31 Naim Alkhouri, Carl LaCerte, Jeffrey Edwards, Fred Poordad, Eric Lawitz, Lois Lee, Sharon Karan, Sangeeta Sawhney, Mary Erickson, Leigh MacConell, Luna Zaru, Jianfen Chen, Jason Campagna
Fibrosis stage is a strong predictor of nonalcoholic steatohepatitis (NASH) outcomes. Two blinded studies evaluated the pharmacokinetics, pharmacodynamics and safety of obeticholic acid (OCA) in subjects with staged NASH fibrosis or cirrhosis.
-
Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use Liver Int. (IF 6.7) Pub Date : 2024-01-31 Christos Siafarikas, Chris J. Kapelios, Margarita Papatheodoridi, John Vlachogiannakos, Nikolaos Tentolouris, George Papatheodoridis
Type 2 diabetes mellitus (T2DM) and liver cirrhosis are clinical entities that frequently coexist, but glucose-lowering medication options are limited in cirrhotic patients. Sodium–glucose linked transporter 2 (SGLT2) inhibitors are a class of glucose-lowering medication that act independently of insulin, by causing glycosuria in the proximal convoluted tubule. In this review, we aimed to briefly present
-
Cost-effectiveness study of FIB-4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at-risk population Liver Int. (IF 6.7) Pub Date : 2024-01-30 Huiyul Park, Eileen L. Yoon, Mimi Kim, Sun-Hong Kwon, Donghee Kim, Ramsey Cheung, Hye-Lin Kim, Dae Won Jun
The cost-effectiveness to screen hepatic fibrosis in at-risk population as recommended by several professional societies has been limited. This study aimed to investigate the cost-effectiveness of this screening strategy in the expanded at-risk population recently proposed by several societies.
-
Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study Liver Int. (IF 6.7) Pub Date : 2024-01-30 Mingyue Cai, Wensou Huang, Wei Liang, Yongjian Guo, Licong Liang, Liteng Lin, Lulu Xie, Jingwen Zhou, Ye Chen, Bihui Cao, Jingqiang Wu, Kangshun Zhu
Our retrospective study has suggested encouraging outcomes of lenvatinib combined with PD-1 inhibitor and transarterial chemoembolization (TACE) on advanced hepatocellular carcinoma (HCC). This phase II trial was conducted to prospectively investigate the efficacy and safety of lenvatinib, sintilimab (a PD-1 inhibitor) plus TACE (Len-Sin-TACE) in patients with advanced stage HCC.
-
Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC Liver Int. (IF 6.7) Pub Date : 2024-01-30 Jiwon Yang, Jonggi Choi, Won-Mook Choi, Kang Mo Kim, Han Chu Lee, Ju Hyun Shim
Tumour microenvironment heterogeneity among different organs can influence immunotherapy responses. Here, we evaluated the impact of differential organ-specific responses on survival in patients with advanced-stage hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atezo/Bev).
-
Evidence for the elimination of viral hepatitis B and C in Egypt: Results of a nationwide survey in 2022 Liver Int. (IF 6.7) Pub Date : 2024-01-30 Amr Kandeel, Manal Fahim, Shimaa Abukamar, Hala BahaaEldin, Hanaa Abuelsood, Sahar Samy, Ola Deghedy, Amany Sheta, Amel Naguib, Nancy El Guindy, Amr Youssef, Reham Kamel, Salma Afifi, Moahmed El-Kassas, Khaled Abdelghaffar
Viral hepatitis C (HCV) and B (HBV) were at the top of Egypt's most significant public health challenges, with an estimated 14.7% of its population having antibodies to HCV in 2008. Egypt issued an ambitious action plan in 2014 to eliminate viral hepatitis through strengthening infection control and improving patient care. In 2018, an extensive HCV mass screening campaign was conducted for the entire
-
No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC Liver Int. (IF 6.7) Pub Date : 2024-01-30 Francisca-Dora Copil, Claudia Campani, Marie Lequoy, Philippe Sultanik, Lorraine Blaise, Mathilde Wagner, Nathalie Ganne-Carrié, Violaine Ozenne, Dominique Thabut, Jean-Charles Nault, Vlad Ratziu, Manon Allaire
It has been suggested that in patients with hepatocellular carcinoma (HCC) of metabolic aetiology, the efficacy of immunotherapy may be reduced. The aim was to investigate the impact of metabolic-associated steatotic liver disease (MASLD) and metabolic risk factors (MRF) on the outcomes of Atezolizumab-Bevacizumab (AtezoBev).
-
Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta-analysis Liver Int. (IF 6.7) Pub Date : 2024-01-31 Giuseppe Indolfi, Philippa Easterbrook, Sabrina Giometto, Farihah Malik, Roger Chou, Ersilia Lucenteforte
We evaluated the effectiveness and safety of pan-genotypic regimens, glecaprevir/pibrentasvir (GLE/PIB), sofosbuvir/velpatasvir (SOF/VEL), and sofosbuvir/daclatasvir (SOF/DCV) and other direct-acting antivirals (DAA) regimens for the treatment of hepatitis C virus (HCV)-infected adolescents (12–18 years), older children (6–11 years), and young children (3–5 years). The purpose of this systematic review
-
Front Cover Liver Int. (IF 6.7) Pub Date : 2024-01-30 Afshan Iqbal, Noemi Van Hul, Lenka Belicova, Agustin A. Corbat, Simona Hankeova, Emma R. Andersson
-
Back Cover Liver Int. (IF 6.7) Pub Date : 2024-01-30 Adam Watson, Louis Petitjean, Mathieu Petitjean, Michael Pavlides
-
May we actually help clinicians select the best systemic treatment for patients with intermediate-stage hepatocellular carcinoma? Liver Int. (IF 6.7) Pub Date : 2024-01-30 Edoardo G. Giannini, Mario Strazzabosco
Systemic treatment of patients with hepatocellular carcinoma (HCC) has shifted from being indicated almost exclusively in those with advanced stage to encompass also patients with intermediate stage, according to the Barcelona clinic liver cancer (BCLC) staging system.1 This treatment migration towards an earlier stage of disease is mainly a consequence of the encouraging results reported in registration
-
Cell type-specific actions of thyroid hormones in nonalcoholic steatohepatitis and liver fibrosis Liver Int. (IF 6.7) Pub Date : 2024-01-30 Tobias Puengel, Frank Tacke
Nonalcoholic fatty liver disease (NAFLD), or metabolic dysfunction-associated steatotic liver disease (MASLD), represents the most common cause of chronic liver disease, and its prevalence is expected to rise further in the near future. Chronic, low-grade, sterile inflammation, which is orchestrated by hepatocytes and various resident or freshly infiltrated immune cells in relation to liver injury
-
Monitoring of hepatitis E virus in wastewater can identify clinically relevant variants Liver Int. (IF 6.7) Pub Date : 2024-01-30 Fiona Rau, Carina Elsner, Toni Luise Meister, André Gömer, René Kallies, Ulf Dittmer, Eike Steinmann, Daniel Todt
Hepatitis E virus (HEV) is prevalent worldwide and can cause persistent infection with severe morbidity. Antiviral treatment approaches can lead to the emergence of viral variants encoding escape mutations that may impede viral clearance. The frequency of these variants remains unknown in the human population as well as environment due to limited comprehensive data on HEV diversity. In this study,
-
Novel insights into metabolic-associated steatotic liver disease preclinical models Liver Int. (IF 6.7) Pub Date : 2024-01-30 Rocío Montero-Vallejo, Douglas Maya-Miles, Javier Ampuero, Franz Martín, Manuel Romero-Gómez, Rocío Gallego-Durán
Metabolic-associated steatotic liver disease (MASLD) encompasses a wide spectrum of metabolic conditions associated with an excess of fat accumulation in the liver, ranging from simple hepatic steatosis to cirrhosis and hepatocellular carcinoma. Finding appropriate tools to study its development and progression is essential to address essential unmet therapeutic and staging needs. This review discusses
-
A Transformer-Based microvascular invasion classifier enhances prognostic stratification in HCC following radiofrequency ablation Liver Int. (IF 6.7) Pub Date : 2024-01-23 Wentao Wang, Yueyue Wang, Danjun Song, Yingting Zhou, Rongkui Luo, Siqi Ying, Li Yang, Wei Sun, Jiabin Cai, Xi Wang, Zhen Bao, Jiaping Zheng, Mengsu Zeng, Qiang Gao, Xiaoying Wang, Jian Zhou, Manning Wang, Guoliang Shao, Sheng-xiang Rao, Kai Zhu
We aimed to develop a Transformer-based deep learning (DL) network for prognostic stratification in hepatocellular carcinoma (HCC) patients undergoing RFA.
-
Different minimal alcohol consumption in male and female individuals with metabolic dysfunction-associated fatty liver disease Liver Int. (IF 6.7) Pub Date : 2024-01-23 Yixuan Zhu, Xiaoming Xu, Zhiwen Fan, Xiaoyan Ma, Fajuan Rui, Wenjing Ni, Xinyu Hu, Qi Gu, Junping Shi, Chao Wu, Yee Hui Yeo, Jie Li
The relationship between moderate alcohol intake and health outcomes among individuals with metabolic dysfunction-associated fatty liver disease (MAFLD) is complex. Our aim was to investigate the association of minimal alcohol consumption with all-cause and cause-specific mortality among MAFLD individuals of different genders.
-
Penetrance, cancer incidence and survival in HFE haemochromatosis—A population-based cohort study Liver Int. (IF 6.7) Pub Date : 2024-01-23 Benedikt Schaefer, Lorenz M. Pammer, Bernhard Pfeifer, Sabrina Neururer, Maria R. Troppmair, Marlene Panzer, Sonja Wagner, Elke Pertler, Christian Gieger, Florian Kronenberg, Claudia Lamina, Herbert Tilg, Heinz Zoller
Haemochromatosis is characterized by progressive iron overload affecting the liver and can cause cirrhosis and hepatocellular carcinoma. Most haemochromatosis patients are homozygous for p.C282Y in HFE, but only a minority of individuals with this genotype will develop the disease. The aim was to assess the penetrance of iron overload, fibrosis, hepatocellular carcinoma and life expectancy.
-
Thyroid function, adipokines and mitokines in metabolic dysfunction-associated steatohepatitis: A multi-centre biopsy-based observational study Liver Int. (IF 6.7) Pub Date : 2024-01-23 Matina Kouvari, Laura Valenzuela-Vallejo, Evangelos Axarloglou, Ornella Verrastro, Georgios Papatheodoridis, Geltrude Mingrone, Jacob George, Christos S. Mantzoros
Thyroid axis is currently under investigation as a therapeutic target in metabolic dysfunction-associated steatotic liver disease (MASLD). Thyroid function was examined herein in the full spectrum of disease.
-
Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods Liver Int. (IF 6.7) Pub Date : 2024-01-22 Maria Paola Anolli, Sara Uceda Renteria, Elisabetta Degasperi, Marta Borghi, Floriana Facchetti, Dana Sambarino, Riccardo Perbellini, Sara Monico, Ferruccio Ceriotti, Pietro Lampertico
Management of chronic hepatitis delta (CHD) requires reliable tests for HDV RNA quantification. The aim of the study was to compare two extraction methods for the quantification of HDV RNA in untreated and bulevirtide (BLV)-treated CHD patients.